Takeda Pharmaceutical Co. Ltd. · TSE:4502

Takeda Pharmaceutical — FY2019 Earnings Presentation

33 slides from Takeda Pharmaceutical's earnings presentation, 2020

  1. Slide 1: va “ed;

    ae va “ed; 2019FF BORE OEPICDWT 2020 ROBWHSRERNOBIEC BACASBLUESOR—AlCMHTFSI=SyY KAYAK 2020455138 a |

  2. Slide 2: w i j

    $ w rP S T I E 8 FE tyP Sw r T P w or y e m P x S P y x g i S Tl w i x i yP v w r P v x P P P P lx x x P g y y v g y x x j x P y i xsyv P mc ct gr k S w y x w xsyX k w y x w x P w r x y k S yPT P P lx x x xm syv x tgr w e t x sT w gr e t w e r i gv om wyP xX tv df i wP y w gr y Rx wv i S w rP t yP l

  3. Slide 3: One Takeda

    01. 02. 03. 04. One Takeda 2019F ROE’ ¢ Rik aE GAZ Bd Fe) VN DS lok OiRIZSOME 20204 2 ielc msi Aiac BUDSMR \\ i Ke | i;

  4. Slide 4: One Takeda

    | One Takeda 01. One Takeda

  5. Slide 5: O D C - O - - I -5 O D C O O

    1 9 0 1 2 5 O 9 D C - 10 O - - I -5 O D C O 5 O D 2 O 1 - V D C 0 1 O 4 D 5 1 D C1

  6. Slide 6: k e d a T

    0 , , T 9 T o 0 , , C k e 9 d 4 4 45 83 a 4 4 3 3 3 9 T O 43 4 3 4 12 r 7 4 T n 4 12 T n 7 12 7

  7. Slide 7: g N O N N ”

    :OI - 1 9 g N O N N ” C:D § N I N § N - N I A D N N N N T N N N § TN 9 N IO H C 1 K8 N N 8 1 C:D § g IN T g og § N N H § gIO N N N N V § A V N

  8. Slide 8: d1 , e3 , - a8 *'1! O +/'&%5 C 3"40,2 T R 98

    d1 , e3 , 5 2 18 8 - 8 8 98 a8 *'1! O 8 +/'&%5 C 3"40,2 40 T R 98 $ #( -. e ) 8 5 O R O 8 M M O d 9 n 0 V I D 8 k 8 O T

  9. Slide 9: | 2019S Dies & Sei

    | 2019S Dies & Sei 2019 EO i615 Ci 02.

  10. Slide 10: B eBa T

    n B T T eBa , T . n eBa n or n 1 7 n T. 1 7 n -. CE, D n BA iA B . - CE D - T p gB n , T 30452/ I s T , - 1 7 36 9 8 C D B . B . B B B B

  11. Slide 11: a D T

    ( D a % D T ( eXg D ( tE i f ( Dr + ( n P M ( ( b ob l y ) ) - * ( ) . ) . 50960 0 T + 0 7 6 2 ob lb +1907 56 % a F ( - a I a D DA G( - D DA F( - ( - N ( . a F( - a m I Io p 8 3006 Rh 42 8 e P F fh R ( - N Rh ( . - rt p a 8 D a G % 50960 0a 210 SF c iF S( ( U G a F( ( a 50960 0a G

  12. Slide 12: HAORXMEOmReS cC-RLEMBNILEVA

    12 HAORXMEOmReS cC-RLEMBNILEVA 4ttO2019F SF Sih italss Luss HAO Ranke =O 20204 50_b Fill 9%| 14% SOURCE: EvaluatePharma®, April 2020, Evaluate, Ltd

  13. Slide 13: A E B A I I I A

    0 A E 5 1 B 0 A I 2 I I 0 A 8 E ./, ./, ./, 3 2 4 D E1 I I 2 I T7 9 I T7

  14. Slide 14: %C E O . +

    %C 2 0 8 E O 92 01 0 . 6 0 + 1 2 R R 3 % C %C C C 9 C 2 14

  15. Slide 15: SPRUE ED VI DST VICKSR

    SPRUE ED VI DST VICKSR 03. Hea RGA FC PFS NAFIAWACKES RISS MER 15

  16. Slide 16: ~ > > 8> > > > 8> > > > > > >

    ~ 3 4 3 3 > > 0 1 4 8> > > > 5 8> > 8 9 > > > > 5 0 > > > 2 > 16

  17. Slide 17: U RSV XY`[ \_Z^]VTV

    12 U RSV XY`[ \_Z^]VTV W 4 302 5#-! *MGL@J%04+5 9 02 5#- &@GBM@N<>>DG@ *@F<LHEHBD> 5#- F<EDBG<G>D@K 'HKDGHICDED> F<JD=<NDJ 5#- %/7LJ<GKIE<GL 5#- /.&+5 'KHIC<BDLDK 5#- FH=H>@JLDGD= .04%.%@OHG %H7+B! %17+&! 5#-! &'' 5#- .04%.%64 FH=H>@JLDGD= .04%.%@OHG '6 5#-*;:31 *#',2 #.60$3+) 5#- .04%.%,2 K> 6%%&'6

  18. Slide 18: 2020 outlook

    ] 2020S lcmise BCBS Sm 04. 2020 2 ile BIE ABe BUSSME

  19. Slide 19: o E sa

    9 0 3 2 1 0 )( ( )( e nb o E sa * ) 1573sa ,(( .* nb ) e o E 368 g (. ) 1573 368( g ).- *( e nb S g . . ( ( i V PI r O D R(ÖæßÒÑäÙHZoé15942 êÂnqÀ`N/Á§¡Cs \_ΑÌ]£ÁDžÏ¯¼§ÍÈ¡iUdƽÁ\{Á3µÍ˜/ÀDžÃj´¼ªÌÆ ¶Ð¢Csá15942 Ã( ( =@ÂCs\{Á3³¼˜/ÀDžÏŵ°¾ÃÀ§¾iUd½LÀF*Á)»­~©¼ªÌ¡ CsÂ( ( =@\{ GðÂ~©SÏT³¼§Æµ¢³«³À¬Ë¡1

  20. Slide 20: O C V

    2020F RUBRIC MITER ECBUSSRE 20200 ROBES : SASANOTIUNAIK ERE MEOH —————_ Zz See-Zees Po meBLU 4YNIb AUSSI A t= (ie FAA —BCtVSABREO | EBRSODEDRALUY y TRUE YY So Be AIM (CHtBESR9r—T1 ORR CA EDAD 2a FES BUSSE DWARF) (15-1 O _ VAILA RUE FAA kL FLS—OphR LNLY DIRE éE JY + DP RERMO COVID-19(CxWI FS ae Fo LI

  21. Slide 21: APPENDIX

    21 APPENDIX Takeda Pharmaceutical Company Limited

  22. Slide 22: Appendix

    Appendix AML acute myeloid leukemia L-ASA low dose aspirin ARD acid-related diseases MLD metachromatic leukodystrophy A/ CD Crohn‘s disease MM multiple myeloma CHAWI congenital hemophilia A with inhibitors NME new molecular entity CML chronic myeloid leukemia NSCLC non-small cell lung cancer CMV Cyt

  23. Slide 23: I F Cr

    I - - C - .- 0 F Cr 7 231 I I 8 o o 9 I I: 4 4 8 9 A G A F G G 6 231 eI 4 C FI 4 o 7S I R 4 4 7 5

  24. Slide 24: I C Fa

    I IF C 0 1) 92 Iha C d id Eh s y r i Fa g i r I S d F t o i a C n i Ei G C E C I C Fa I *( d EhaRl G r w I i I a E r 0 I i a 0 g i S S i e I i e FS a ” h 0 1 0 a h EhaRl E r g I 0 IF GU Ei d F t o i a g i a a g g i ” a

  25. Slide 25: R I S

    R I 2 S SD T SD S R () 8 R I I A SD I 2 2I I2 D S R I S F 2I 2 I2 D SD 2I I S 2I I I SD 2I A I SB () 2 () I A SD I SB S I R I () SD R I 2 2 S 2I i R R S SD R 8 8 R 2 D S () D S () 2I D 2I 8E 2

  26. Slide 26: Core Earnings

    0 13#$ 14#$ 'A1 5 16,917 17,778 + 5.1% /*&C 60 (400) 8 (221) (160) !>4'A !>4 16,757 17,219 + 2.8% △ ,5 1,393 1,293 - B )9 2,741 0%=2 1,197 1,238 0%=2.( 231 635 @2 (67) (328) ,-?7<3 217 312 +" 56 (513) ;:<36 116 92 △ Core Earnings 3,142 2,883 8.2% /*&C 30 138 8 (161) (73) △ !>4'A !>4 Core Earnings 3,

  27. Slide 27: % e E S

    21 0 .342 6 7 S 9 .342 % e 5 5 E S 9 9 % - - e 8* % , 8 , % , % %- 8 % * , * 8* - 8 *, %* 8 ** S 8% - S 8,* ,* % -- 8 - 8 8,,* 8% -* % % * , % ,- 8 8,,* - C r %% %- 8** %,% 8 8 * -, P % * % % * % % % - % 8,,* 8 8 8% 8 8 % 8 8% - % % P % ,* 8% - , %% * %* 8 , 8 % 016 7 % % o 6 7 -*% -*% 8 1 9 1 1 *0

  28. Slide 28: 0C y C

    8 / 2 0C 1 -893 -893 172396 574 S -893 -893 dS r P l n i S y n i n i y y , % y C Uy % , y % % S y , , S % , %, y % % % , , % , E % e , , % % % o y % % % % % g e % % . 0 % % % , , 28

  29. Slide 29: g S r

    / 0 21 9 -893 U -893 P U 172396 574 e -893 -893 EC P nC C o i S %, % %, % % , ,, , % , g %% ,, % , % S , % , %, ,% , , r % % r nC % % nC % nC % % % , %% % y %, % % % % % %% % o % % lo %,% , % , % % , d % , %, , % %% , . 0 % % % 29

  30. Slide 30: - ,53 e - , e C o / r 2 7e / r

    2 0 0 - ,53 e 2 7 98 2 - , e 2 7 13 3 98 7 C 3 3 3 3 o 4 / r 2 7e / r 2 7e / 13 3 / 13 3 / / 30

  31. Slide 31: % + % , , + % . % + + % % ,

    % + % , , + % . 5 % + + % 4 % , % + 3 , % % + + , 03 , 2678 9 %+ ,+ , 3 267 % , 3 267 % + 3 267 , % 3 267 , 3 . 267 , 267 1 5 + 8 9 + , + +,, 31

  32. Slide 32: B A B

    I D 0 . 12 / B 6 87 1 E , % + % , 0346 87 9 %+ ,+ , 698 * 1 034 % 1 034 % 7 D A 4 , 1 034 , 5 D7 1 034 1 . 034 , 5T 4 034 %, + , 034 + I D 4 * 1 034 + 1 % I D 4 5034 % 1 034 1 034 + , % I D 0 . 12 / B 3 1 034 1 , % % 1 % +% 1 0 . 12 / , 1 2 , +% B 3 A B , * 9 B A 5 1 1 1 A 5 0 B 6ID A B T 9 2B EB 6I

  33. Slide 33: T h i

    / T , h * ** i * 0 26 / - , * , AEPE r i , D I AEPE n 5897 E B E S nD I GE * , 5897 D I AEPE , ne0 26 / - , o5 8 9 7 E3 1 - - 4 0 26 / - 3 - ne0 26 / - N *** 3 - * r SGG iT S . 1 - T 89 T ) A BT2 0 3. 1 - G 89 T ) A BT2 0 3. 1 - ) ( T ) P 89 T ) ( * A BT n. 1 - T A B T n. 1 - 89 T2 0 3. 1 - Th 1 4 S

Takeda Pharmaceutical Company — FY2019 Earnings Presentation on 6ix